Talphera/$TLPH
1D1W1MYTD1Y5YMAX
About Talphera
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
- Ticker
- $TLPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 12
- Headquarters
- San Mateo, United States
- Website
- talphera.com
Talphera Metrics
BasicAdvanced
$62M
-
-$0.24
0.70
-
Price and volume
Market cap
$62M
Beta
0.7
52-week high
$1.57
52-week low
$0.50
Average daily volume
270K
Financial strength
Current ratio
4.295
Quick ratio
4.077
Long term debt to equity
45.113
Total debt to equity
45.113
Profitability
Gross margin (TTM)
-670,300.00%
Net profit margin (TTM)
-1,507,600.00%
Operating margin (TTM)
-1,474,700.00%
Management effectiveness
Return on assets (TTM)
-42.55%
Return on equity (TTM)
-143.36%
Valuation
Price to revenue (TTM)
80,000
Price to book
4.32
Price to tangible book (TTM)
4.32
Price to free cash flow (TTM)
-6.215
Free cash flow yield (TTM)
-16.09%
Free cash flow per share (TTM)
-0.193
Growth
Revenue change (TTM)
-96.30%
Earnings per share change (TTM)
-40.55%
3-year revenue growth (CAGR)
-84.19%
10-year revenue growth (CAGR)
-63.67%
3-year earnings per share growth (CAGR)
-56.36%
10-year earnings per share growth (CAGR)
-32.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.